Name: Rethinking Medications: Truth, Power, and the Drugs you Take (en Inglés)
SKU: 64202108
Price: 445.64 MXN
Availability: InStock
Author: Jerry Avorn Md
ISBN: 9781668052846

portada Rethinking Medications: Truth, Power, and the Drugs you Take (en Inglés)

Rethinking Medications: Truth, Power, and the Drugs you Take (en Inglés)

Formato

Libro Físico

Editorial

Simon and Schuster

Autor

Jerry Avorn Md

Idioma

Inglés

N° páginas

512

Encuadernación

Tapa Dura

ISBN13

9781668052846

Rethinking Medications: Truth, Power, and the Drugs you Take (en Inglés)

Jerry Avorn Md (Autor) · Simon and Schuster · Tapa Dura

Libro Nuevo Importado

Envío: 20 a 25 días háb.

$ 891.27$ 445.64

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 99 unidades

$ 445.64

Llega entre el 12 Oct y el 20 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Rethinking Medications: Truth, Power, and the Drugs you Take (en Inglés)"

A leading medical expert explains why too many of the medications Americans take are poorly evaluated, overpriced, or pose unwarranted risks--and what we can do to fix that. Groundbreaking research has given us many remarkable new medicines, but America's drug evaluation process, once the envy of the world, is being seriously compromised. Under pressure from drugmakers, the FDA has been lowering its approval standards and has let poorly effective or risky products enter the market--while our prescription prices, the highest in the world, put crucial treatments beyond the reach of many. In Rethinking Medications, Dr. Jerry Avorn explains how we got here and what we can do to ensure that our medicines are dependably effective, safe, and affordable. Part of the problem is the power of pharma's biggest-in-Washington lobbying clout, which influences members of Congress from both parties. That leverage is extended by the FDA's growing dependence on fees the industry pays to get its drugs approved. The increasingly revenue-driven US healthcare system shapes the way doctors prescribe medications--sometimes to the detriment of their clinical decisions. Based on his decades of practice and research at Harvard Medical School and his role at the very center of many of these controversies, Dr. Avorn presents compelling clinical illustrations of these issues across the medical spectrum: from cancer drugs to opioids, from treatments for rare diseases to psychedelics. Throughout, he offers practical steps that consumers, policymakers, and practitioners can take to address these problems--at a moment when our assumptions about scientific evidence, regulation, pricing, and the role of government are being contested as never before.